Real-world research reflects lasting value of remdesivir

25 April 2022
biotech_production_bottles_big

The first treatment to be offered for people with COVID-19 has proven to be of continued use in combating the disease.

New data on Veklury (remdesivir) in COVID-19 have been presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID 2022).

Findings from two studies provide insights on the use of Gilead Sciences' (Nasdaq: GILD) Veklury for people in and out of hospital with the disease.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory

Companies featured in this story

More ones to watch >


More Features in Pharmaceutical